Benefit‐cost analysis of addiction treatment in Arkansas: Specialty and standard residential programs for pregnant and parenting women

Substance Abuse

Volumn 23, Issue 1, 2002, Pages 31-51

  McCollister, Kathryn E ^a   French, Michael T ^a   Cacciola, John ^b   Durell, Jack ^b   Stephens, Raymond L ^c  

^a UNIVERSITY OF MIAMI   (United States)

^b DeltaMetrics   (United States)

^c ARKANSAS DEPARTMENT OF HEALTH   (United States)

Author keywords

Addiction treatment; Benefit cost analysis; Pregnant and parenting women

Indexed keywords

ADDICTION; ARTICLE; CHILD PARENT RELATION; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; PREGNANCY; PREGNANCY COMPLICATION; RESIDENTIAL CARE; STATISTICS; TREATMENT OUTCOME; UNITED STATES; ACCURACY; ADDICTION SEVERITY INDEX; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HEALTH CARE POLICY; HEALTH PROGRAM; MAJOR CLINICAL STUDY; MONEY; OUTCOMES RESEARCH; PARENT; QUESTIONNAIRE; SELF REPORT;

ARKANSAS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; PARENTING; PREGNANCY; PREGNANCY COMPLICATIONS; RESIDENTIAL TREATMENT; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 0036490405     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897070209511473     Document Type: Article

References (63)

1. Lee MJ: Marihuana and tobacco use in pregnancy. Obstet Gynecol Clin North Am 1998; 25:65-83
2. Bauer CR: Perinatal effects of prenatal drug exposure, neonatal aspects. Clin Perinat 1999; 26:87-106
3. De Ville KA, Kopelman LM: Moral and social issues regarding pregnant women who use and abuse drugs. Obstet Gynecol Clin North Am 1998; 25:237-254
4. Reed BG: Drug misuse and dependency in women: The meaning and implications of being considered a special population or minority group. Int J Addict 1985; 20:13-62
5. National Institute on Drug Abuse: National Pregnancy and Health Survey: Drug use among women delivering livebirths: 1992. Washington, DC: US Department of Health and Human Services; 1996
6. DeltaMetrics: Problem Severity and Treatment Outcomes of Pregnant and Parenting Women in Specialty and Standard Residential Substance Abuse Treatment: Final report. Arkansas: TOPPS 1; 1999
7. French MT, Salomé HJ, Krupski A, McKay JR, Donovan DM, McLellan AT, Durell J. Benefit-cost analysis of residential and outpatient addiction treatment in the state of Washington. Eval Review 2000; 24(6):609-634
8. French MT, Salomé HJ, Sindelar JL, McLellan AT: Benefit-Cost Analysis of Substance Abuse Treatment: Methodological Guidelines and Application Using the DATCAP and ASI. Health Services Research; in press
9. French MT, Salomé HJ, Carney M: Using the DATCAP and ASI to Estimate the Costs and Benefits of Residential Addiction Treatment in the State of Washington. Working paper, University of Miami School of Medicine; 2001a
10. French MT, McCollister KE, Sacks S, McKendrick K, De Leon G: Benefit-cost analysis of a modified therapeutic community for mentally ill Chemical Abusers. Evaluation and Program Planning; in press
11. Cartwright WS: Cost-benefit and cost-effectiveness analysis of drug abuse treatment services. Eval Rev 1998; 22:609-636
12. French MT: Economic evaluation of drug abuse treatment programs: Methodology and findings. Am J Drug Abuse 1995; 21:111-135
13. French MT: Economic evaluation of alcohol treatment services. Eval Progr Plann 2000; 23:27-39
14. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996
15. Drummond MF, O'Brien CP, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press; 1997
16. Kenkel D: On valuing morbidity, cost-effectiveness analysis, and being rude. J Health Econ 1997; 16:749-757
17. Sindelar JL, Manning WG: Treating drug abusers effectively. In: Egertson JA, Fox DM, Leshner AI, eds. Cost-Benefit and Cost-Effectiveness Analysis: Issues in the Evaluation of the Treatment of Illicit Drug Abuse. Maiden, MA: Blackwell; 1997
18. Yin D, Forman HP: Health-care and cost-benefit and cost-effectiveness analysis: An overview. J Vase Interv Radiol 1995; 6:311-320
19. Lave LB, Joshi SV: Benefit-cost analysis in public health. Annu Rev Public Health 1996; 17:203-219
20. Johanneson M: Theory and Methods of Economic Evaluation of Health Care. Dordrecht: Kluwer Academic; 1996
21. Tolley G, Kenkel D, Fabian R: Valuing Health for Policy: An Economic Approach. Chicago: The University of Chicago Press; 1994
22. Zarkin GA, French MT, Anderson DW, Bradley CJ: A conceptual framework for the economic evaluation of substance abuse interventions. Eval Progr Plann 1994; 17:409-418
23. Hans SL: Demographic and psychosocial characteristics of substance-abusing pregnant women. Clin Perinatol 1999; 26:55-74
24. Flanagan P, Kokotailo P: Adolescent pregnancy and substance use. Clin Perinatol 1999; 26:185-200
25. Lief NR: The drug user as a parent. Int J Addictions 1985; 20:63-97
26. Marwick C: Challenging report on pregnancy and drug abuse. JAMA 1998; 280:1039-1040
27. Stichler JF, Weiss M, Wight NE: Examining the "cost" of substance abuse in pregnancy: Patient outcomes and resource utilization. J Perinatol 1998; 18:384-388
28. Svikis D, Golden AS, Huggins GR, Pickens RW, McCaul ME, Velez ML, Rosendale CT, Brooner RK, Gazaway PM, Stitzer ML, Ball CE: Cost-effectiveness of treatment for drug-abusing pregnant women. Drug Alcohol Depend 1997; 45:105-113
29. Svikis D, McCaul M, Feng T, Stuart M, Fox M, Stokes E: Drug dependence during pregnancy: Effect of an on-site support group. J Reprod Med 1998; 799-805
30. Anderson DW, Bowland BJ, Cartwright WS, Bassin G: Service-level costing of drug abuse treatment. J Subst Abuse Treat 1998; 15:201-211
31. Goodman AC, Holder HD, Nishiura E, Hankin JR: An analysis of short-term alcoholism treatment cost functions. Med Care 1992; 30:795-810
32. Goodman AC, Nishiura E, Hankin JR, Holder HD, Tilford JM: Long-term alcoholism treatment costs. Med Care Res Rev 1996; 53:441-464
33. Goodman AC, Nishiura E, Hankin JR: Short-term drug abuse treatment costs and utilization: A multi-employer analysis. Med Care 1998; 36:1214-1227
34. French MT, Dunlap LJ, Zarkin GA, McGeary KA, McLellan AT: A structured instrument for estimating the economic cost of drug abuse treatment. The drug abuse treatment cost analysis program (DATCAP). J Subst Abuse Treat 1997; 14:1-11
35. French MT, McGeary KA: Estimating the economic cost of substance abuse treatment. Health Econ 1997; 6:539-544
36. Salomé HJ, French MT: Using cost and financing instruments for economic evaluation of substance abuse treatment services. In: Galanter M, ed. Recent Developments in Alcoholism, Vol 14: Services Research in the Era of Managed Care, Section 3. New York: Plenum Press; 2000
37. Holder HD, Shachtman RD: Estimating health care savings associated with alcoholism treatment. Alcohol Clin Exp Res 1987; 11:66-73
38. French MT, Mauskopf JE, Teague JL, Roland EJ: Estimating the dollar value of health outcomes from drug-abuse interventions. Med Care 1996; 34:890-910
39. Rajkumar AS, French MT. Drug abuse, crime costs, and the economic benefits of treatment. J Quant Crim 1997; 13:291-323
40. Harwood HJ, Hubbard RL, Collins J, Rachal JV: A cost-benefit analysis of drug abuse treatment. Res Law Policy Studies 1995; 3:191-214
41. Mauser E, Van Stelle KR, Moberg DP: The economic impact of diverting substance-abusing offenders into treatment. Crime Deliquency 1994; 40:568-588
42. Plotnick RD: Applying benefit-cost analysis to substance use prevention programs. Int J Addict 1994; 29:339-359
43. Sirotnik KA, Bailey RG A cost-benefit analysis for a multi-modality heroin treatment project. Int J Addict 1975; 10:443-451
44. Tabbush V: The Effectiveness and Efficiency of Publicly funded Drug Abuse Treatment and Prevention Programs in California: A benefit-cost Analysis. University of California Press; 1986
45. Gerstein DR, Johnson RA, Harwood HJ, Fountain HK, Suter N, Malloy K: Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA), General Report. Sacramento, CA: California Department of Alcohol and Drug Program; 1994
46. Institute of Medicine (IOM): Gustein D, Harwood H, eds. Treating Drug Problems: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems. Washington, DC: National Academy Press; 1990
47. McLellan AT: An improved diagnostic evaluation instrument for substance abuse patients. J Nerv Ment Dis 1980; 168:26-33
48. McLellan TA, Kushner H, Metzger D, et al.: The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9:199-213
49. Rosser R, Kind P: A scale of valuations for status of illness: Is there a social consensus? Int J Epidemiol 1978;7:347-358
50. Mauskopf JA, French MT: Estimating the value of avoiding morbidity and mortality from foodborne illnesses. Risk Analys 1991; 11(4):619-632.
51. Mauskopf JA, Bradley CJ, French MT: Benefit-cost analysis of hepatitis B vaccine programs for occupationally exposed workers. J Occup Med 1991; 33(6):691-698.
52. American Hospital Association: American Hospital Association Hospital Statistics. Chicago: American Hospital Association; 2000
53. Physician Fee Schedule for Arkansas State. American Medical Association; 1999
54. Harwood H, Fountain D, Livermore G: The Economic Costs of Alcohol and Drug Abuse in the United States, 1992. (98-4327).
55. Rockville, MD: National Institute on Drug abuse and National Institute on Alcohol Abuse and Alcoholism; 1998
56. Ball JC, Ross A: The Effectiveness of Methadone Maintenance Treatment. Patients, Programs, Services, and Outcome. New York: Springer; 1991
57. StataCorp: Stata Statistical Software: Release 6.0. College Station, TX: Stata Corporation; 1999
58. Rouse B, Kozel N, Richards L, eds.: Self-Report Methods of Estimating Drug Use: Meeting Current Challenges to Validity. Rockville, MD: National Institute on Drug Abuse; 1985
59. Drake S: Self-report among injecting drug users: A review. Drug Alcohol Depend 1998; 51:253-263
60. Weatherby NL, Needle R, Cesari H, Booth R, McCoy CB, Watters JK, Williams M, Chitwood DD: Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Progr Plann 1994; 17:347-355
61. Blose JO, Holder HD: The utilization of medical care by treated alcoholics: Longitudinal patterns by age, gender, and type of care. J Subst Abuse 1991; 3:13-27
62. Holder HD, Lennox RD, Blose JD: The economic benefits of alcoholism treatment: A summary of twenty years of research. J Employee Assist Res 1992; 1:63-82
63. Holder HD, Blose JO: The reduction of healthcare costs associated with alcoholism treatment: A 14-year longitudinal analysis study. J Stud Alcohol 1992; 53:293-302